Founded in 2005, AmbioPharm is a leading peptide CDMO (Contract Development and Manufacturing Organization) with one of the largest peptide production capacities globally. Specializing in peptide-based Active Pharmaceutical Ingredients (APIs), AmbioPharm develops highly efficient manufacturing processes at various scales, from small to large, in their state-of-the-art facilities in South Carolina, USA and Shanghai, China. With a focus on quality and compliance, both locations have undergone multiple FDA inspections with excellent outcomes.

AmbioPharm offers a wide range of products and services to pharmaceutical, research, and biotech companies. Their services include GMP (Good Manufacturing Practice) peptide synthesis, custom organic synthesis, vaccine services, and analytical development and validation. They also provide generic peptide APIs for established commercial markets worldwide.

AmbioPharm's unique business model allows them to produce high-quality products at lower costs compared to competitors. They offer fast turnaround times, with custom peptides reviewed and released by their in-house Quality Control Unit in as little as 3-4 weeks. Additionally, AmbioPharm can efficiently manufacture peptides of any batch size.

With their experienced management team and state-of-the-art facilities, AmbioPharm is setting a new standard for peptide API manufacturing and services